Neoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial Carcinoma
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma (NCT04672330) | RenJi Hospital | 2020-12-01 |
Track Neoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.